House passes its version of the opioid bill package
House and Senate versions must be reconciled in committee before being passed by Congress and signed into law. Read More »
House and Senate versions must be reconciled in committee before being passed by Congress and signed into law. Read More »
CVS Health President and CEO to speak to investors at the conference on May 24. Read More »
Nine informational data and research posters on atypical antipsychotic cariprazine to be presented. Read More »
Alex Brill, CEO of Washington, D.C.-based economic policy consulting firm Matrix Global Advisors, recently published a strategic proposal suggesting how payors can support biosimilar utilization. Read More »
Pfizer will acquire crisaborole, a treatment for eczema, in the deal. Read More »
Cigna Collective Care helps close the gaps in patient care while keeping costs down. Read More »
Fundraising campaign supports American Lung Association's initiative to increase lung cancer awareness and research. Read More »
Cardinal Health's Cordis returns to the drug-eluting stent market. Read More »
Agreement combines pharmaceutical industry expertise with a commitment to low prices. Read More »
Two clinical trials show tear production increased in patients suffering from dry eye disease. Read More »
McKesson's ClaimsXten and ClaimsXten Select will integrate with TriZetto's QNXT to simplify claims management. Read More »
New certificate program added to ASHP online continuing education program for pharmacists and pharmacy technicians. Read More »
Second video spot debuts; urges pharmacy personnel to volunteer and vote for their preferred candidates. Read More »
Aetna customers to receive coordinated care from Providence hospitals and health care providers. Read More »
Four posters on nebivolol and fixed-dose combination of nebivolol and valsartan were presented. Read More »
Communication key to developing treatment goals and disease management plan. Read More »
Updates on CVS Health's goals and initiatives for 2015 presented. Read More »
Pfizer will showcase its growing portfolio of innovative treatments for a variety of cancers. Read More »
Targeted treatment with Tecentriq approved; it is the first PD-L1 inhibitor approved by FDA for urothelial carcinoma. Read More »
Fourteen presentations will present results of avelumab treatments for seven different cancer types. Read More »